LAVA Therapeutics NV held an extraordinary general meeting of shareholders on November 7, 2025. Shareholders approved the conditional appointment of Owen Hughes as executive director, and Thomas Burns, Bradley Sitko, and Maricel Montano as non-executive directors. The meeting also approved the granting of discharge to board members for actions up to the meeting date. Additionally, shareholders approved the conditional resolution to enter into a Dutch statutory merger with LAVA Therapeutics New Topco B.V., with the issuance of class A and class B shares to relevant shareholders as part of the merger process.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LAVA Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-108480), on November 07, 2025, and is solely responsible for the information contained therein.